Last reviewed · How we verify

Fundació Privada Eugin — Portfolio Competitive Intelligence Brief

Fundació Privada Eugin pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Clomifene Citrate Clomifene Citrate marketed Selective estrogen receptor modulator (SERM) Estrogen receptor (ER-α and ER-β) Reproductive/Fertility
Progevera Progevera marketed Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 1 shared drug class
  2. Austrian Breast & Colorectal Cancer Study Group · 1 shared drug class
  3. Estetra · 1 shared drug class
  4. H. Lee Moffitt Cancer Center and Research Institute · 1 shared drug class
  5. National Taiwan University Hospital · 1 shared drug class
  6. Oregon Health and Science University · 1 shared drug class
  7. Samsung Medical Center · 1 shared drug class
  8. Shandong Suncadia Medicine Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundació Privada Eugin:

Cite this brief

Drug Landscape (2026). Fundació Privada Eugin — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-privada-eugin. Accessed 2026-05-15.

Related